Lakefront Biotherapeutics (GLPGF) Capital Expenditures (2014 - 2026)

Lakefront Biotherapeutics (GLPGF) has reported Capital Expenditures for 13 consecutive years, with -$144001.7 the latest figure, recorded in Q1 2026.

• On a quarterly basis, Capital Expenditures rose 97.31% year-over-year to -$144001.7 in Q1 2026; TTM through Mar 2026 was -$10.0 million, a 48.16% increase from a year earlier, with the FY2025 full-year figure at -$15.5 million, up 14.44% from the prior year.
• Capital Expenditures was -$144001.7 for Q1 2026 at Lakefront Biotherapeutics, up from -$1.9 million in the prior quarter.
• Over five years, Capital Expenditures peaked at -$144001.7 in Q1 2026 and troughed at -$27.9 million in Q4 2022.
• A 5-year average of -$7.4 million and a median of -$4.7 million in 2024 frame the typical range for Capital Expenditures.
• Across the five-year window, Capital Expenditures sank 31.84% in 2025 and jumped 97.31% in 2026, its largest moves.
• Over 5 years, Capital Expenditures stood at -$27.9 million in 2022, then rose by 27.97% to -$20.1 million in 2023, then jumped by 71.22% to -$5.8 million in 2024, then soared by 67.76% to -$1.9 million in 2025, then soared by 92.29% to -$144001.7 in 2026.
• The last three Capital Expenditures figures came in at -$144001.7 (Q1 2026), -$1.9 million (Q4 2025), and -$3.3 million (Q3 2025), per Business Quant data.